HealingWell
Search Close Search
☰

Disappointing news on ProstVac for mCRPC

Support Forums
>
Prostate Cancer
✚ New Topic ✚ Reply
❬ ❬ Previous Thread |Next Thread ❭ ❭
Posted 9/15/2017 5:20 PM (GMT 0)
Bavarian Nordic is stopping their ProstVac trial because it would be futile to continue. This was the trial for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. Here's their press release:

INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS DISCONTINUATION OF BAVARIAN NORDIC’S PHASE 3 STUDY OF PROSTVAC IN METASTATIC PROSTATE CANCER

As far as I know, the other Prostvac trials are continuing (e.g., combined with Ipi, combined with docetaxel for mHSPC, for active surveillance, and for biochemical recurrence). In general (except for Provenge), immunologicals have been disappointing for prostate cancer.
Posted 9/15/2017 5:24 PM (GMT 0)
That's sad. Too bad it's not working.
Posted 9/15/2017 5:37 PM (GMT 0)
Disappointing and surprised to hear the news....
Posted 9/15/2017 6:57 PM (GMT 0)
This is very surprising. As far as I recall the results of the phase II study were better than Provenge.

Must be disappointing for Madagascar_63.

George
Posted 9/15/2017 7:02 PM (GMT 0)
There may be subgroups who benefit. It once again demonstrates the importance of large randomized clinical trials.
Posted 9/15/2017 7:04 PM (GMT 0)
That is really upsetting. The only thing I'm happy about is that I didn't invest money because I was expecting good news. Apparently, not a good day for this company from that perspective as well (down 50%)
Posted 9/16/2017 12:24 AM (GMT 0)
I had to read that heading 3 times before I figured out it wasn't Pos T vac!
Posted 9/16/2017 3:35 PM (GMT 0)
Is it possible that this result was affected by the approval of enzalutamide eight months after the start of the trial? Adding enza to those who dropped from the trial because of progression or other reasons and who then turned to enza and this was no Prostvac vs placebo? These trials take so long such events are inevitable which contains good and bad.
Posted 9/16/2017 5:10 PM (GMT 0)
tarhoosier-
Anyone who dropped out before the 5-month induction period was not included in the study at all. This was a double-blinded study. After the 5 months of immunological treatment, everyone went on to receive standard of care at their oncologist's discretion - that may have included advanced hormonals, chemo or radiologicals. There's no reason to suppose that the placebo groups received any different subsequent treatment from the ProstVacVF, or the ProstVacVF+tricom groups.

While it's disappointing, we will probably learn a lot from this study. It may help answer many questions about the immunolgical response to prostate cancer, and why it failed to slow progression. Perhaps it will lead to a better solution. CART-T still looks promising.
✚ New Topic ✚ Reply